OS Therapies grants Kerry M. Clem 700K stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
OS Therapies Inc (OSTX) Chief Commercial Officer Kerry M. Clem was granted 200,000 restricted stock units and options to purchase 700,000 common shares on November 10, 2026. The reported direct common-stock position after the RSU transaction was 225,000 shares. Both awards vested 20% on the grant date; the remaining 80% vest in 12 equal quarterly installments from December 31, 2026 through September 30, 2029, provided Clem remains an employee on each vesting date. The options have a $0.89 per-share exercise price and expire November 10, 2036.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock options (right to buy) F2 | 700,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock F1 | 200,000 | $0.00 | $0.00 |
Footnotes (2)
- F1. On November 10, 2026 (the "Grant Date"), the reporting person was granted 200,000 restricted stock units ("RSUs") pursuant to the terms and conditions of a restricted stock unit award agreement and the issuer's amended and restated 2023 incentive compensation plan. Each RSU represents a contingent right to receive one share of the issuer's common stock upon vesting and settlement. 20% of the RSUs vested on the Grant Date, and the remaining 80% vest in 12 equal quarterly installments on the last day of each calendar quarter, commencing December 31, 2026 and ending September 30, 2029, provided that the reporting person is serving as an employee of the issuer on each applicable vesting date.
- F2. On the Grant Date, the reporting person was granted options to purchase 700,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and the issuer's amended and restated 2023 incentive compensation plan. 20% of these options vested on the Grant Date, and the remaining 80% vest in 12 equal quarterly installments on the last day of each calendar quarter, commencing December 31, 2026 and ending September 30, 2029, provided that the reporting person is serving as an employee of the issuer on each applicable vesting date.
Key Figures
Key Terms
restricted stock units financial
contingent right financial
vesting financial
stock option award agreement financial
incentive compensation plan financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did OSTX's Chief Commercial Officer receive?
What is the vesting schedule for Kerry M. Clem's OSTX awards?
AI-generated analysis. How Rhea-AI works. Not financial advice.